Soleno Therapeutics Inc (SLNO) has issued an update.
A revised press release by Soleno Therapeutics, Inc. has corrected a minor reporting error in their financial results for Q4 and the full year of 2023. The adjusted figure for general and administrative expenses is now accurately stated as $4,140 for the quarter ending December 31, 2023, rectifying the previous misstatement of $4,410. This update ensures investors have precise information for their financial assessments.
See more insights into SLNO stock on TipRanks’ Stock Analysis page.
